RBD-7022 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia.

Laura Bonetta reports. These molecules induce the sequence-specific silencing of genes by the process of RNA interference (RNAi) in a variety of organisms, including humans. The RNAi pathway was ...

New research uncovers why certain individuals with disease-causing genes remain symptom-free. Researchers at Columbia ...

Ractigen Therapeutics proudly announces that its Founder and CEO, Dr. Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ...

A leader in small activating RNA (saRNA) drug development ... such as those resulting from epigenetic silencing or gene downregulation. For more information, please visit our website at ...

More information: Seungjae Lee et al, Noncanonical role of ALAS1 as a heme-independent inhibitor of small RNA–mediated silencing, Science (2024). DOI: 10.1126/science.adp9388 ...

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve ...

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat ...

In everyday life, when things turn out the opposite of what you expect, it's usually cause for frustration. In science, it's ...

RNA interference (RNAi), meanwhile ... Nanoparticles Codelivering mRNA and SiRNA for Simultaneous Restoration and Silencing of Gene/Protein Expression In Vitro and In Vivo, ACS Nanoscience ...

Moreover, RNA's AOC treatments are designed to deliver oligonucleotides to tissues. The idea is to combine monoclonal antibodies' properties with oligonucleotides' gene-silencing features.